Shionogi & Co Ltd - Product Pipeline Review - 2016

1 of 4
Shionogi & Co Ltd - Product Pipeline Review - 2016

Summary:

‘Shionogi & Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Shionogi & Co Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shionogi & Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of Shionogi & Co Ltd
- The report provides overview of Shionogi & Co Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Shionogi & Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Shionogi & Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate Shionogi & Co Ltd’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Shionogi & Co Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Shionogi & Co Ltd’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Shionogi & Co Ltd Snapshot

Shionogi & Co Ltd Overview

Key Facts

Shionogi & Co Ltd - Research and Development Overview

Key Therapeutic Areas

Shionogi & Co Ltd - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Shionogi & Co Ltd - Pipeline Products Glance

Shionogi & Co Ltd - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Shionogi & Co Ltd - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Shionogi & Co Ltd - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Shionogi & Co Ltd - Drug Profiles

A-2NTX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

asapiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doripenem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lusutrombopag - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naldemedine tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ospemifene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxycodone hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Agonize NPR1 and NPR2 for Non-Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rovatirelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-010887 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-033188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-117957 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-120083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-222611 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-237648 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-488210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-588410 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-600918 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-707106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 Receptor for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV4 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CB2 for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NPY5R for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Penicillin Binding Protein for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-0379 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STAGR-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Shionogi & Co Ltd - Pipeline Analysis

Shionogi & Co Ltd - Pipeline Products by Target

Shionogi & Co Ltd - Pipeline Products by Route of Administration

Shionogi & Co Ltd - Pipeline Products by Molecule Type

Shionogi & Co Ltd - Pipeline Products by Mechanism of Action

Shionogi & Co Ltd - Dormant Projects

Shionogi & Co Ltd - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

ADX-415

capravirine

doripenem

GSK-364735

GW-810781

lisdexamfetamine dimesylate

lusutrombopag

S-234462

S-288310

S-444823

S-488410

S-5751

S-646240

S-777469

S-8510

teceleukin

varespladib sodium

velneperit

Shionogi & Co Ltd - Company Statement

Shionogi & Co Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Shionogi & Co Ltd, Key Facts

Shionogi & Co Ltd - Pipeline by Indication, 2016

Shionogi & Co Ltd - Pipeline by Stage of Development, 2016

Shionogi & Co Ltd - Monotherapy Products in Pipeline, 2016

Shionogi & Co Ltd - Combination Treatment Modalities in Pipeline, 2016

Shionogi & Co Ltd - Partnered Products in Pipeline, 2016

Shionogi & Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016

Shionogi & Co Ltd - Out-Licensed Products in Pipeline, 2016

Shionogi & Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016

Shionogi & Co Ltd - Pre-Registration, 2016

Shionogi & Co Ltd - Phase III, 2016

Shionogi & Co Ltd - Phase II, 2016

Shionogi & Co Ltd - Phase I, 2016

Shionogi & Co Ltd - Preclinical, 2016

Shionogi & Co Ltd - Discovery, 2016

Shionogi & Co Ltd - Pipeline by Target, 2016

Shionogi & Co Ltd - Pipeline by Route of Administration, 2016

Shionogi & Co Ltd - Pipeline by Molecule Type, 2016

Shionogi & Co Ltd - Pipeline Products by Mechanism of Action, 2016

Shionogi & Co Ltd - Dormant Developmental Projects,2016

Shionogi & Co Ltd - Discontinued Pipeline Products, 2016

Shionogi & Co Ltd, Other Locations

Shionogi & Co Ltd, Subsidiaries

List of Figures:

Shionogi & Co Ltd - Pipeline by Top 10 Indication, 2016

Shionogi & Co Ltd - Pipeline by Stage of Development, 2016

Shionogi & Co Ltd - Monotherapy Products in Pipeline, 2016

Shionogi & Co Ltd - Partnered Products in Pipeline, 2016

Shionogi & Co Ltd - Out-Licensed Products in Pipeline, 2016

Shionogi & Co Ltd - Pipeline by Top 10 Target, 2016

Shionogi & Co Ltd - Pipeline by Route of Administration, 2016

Shionogi & Co Ltd - Pipeline by Molecule Type, 2016

Shionogi & Co Ltd - Pipeline Products by Top 10 Mechanism of Action,
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll